The incidence of breast cancer in Korean women is the highest among women in their fifth decade, while in American women, the incidence is highest among those in their mid-sixth decade or later [2]. One explanation for this difference may be genetic factors. Indeed, several breast cancer-related genes, including ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, STK11, and TP53, have been identified [3]. Among these, BRCA1/2 are the most important and most widely studied genetic risk factors for breast cancer worldwide.

In this issue of Ann Lab Med, Yoo, et al. [4] report the results of genetic testing of BRCA1/2 and the clinical validity of next-generation sequencing-based multi-gene panel testing in a single institution. Although pathogenic variants (PV) were identified not only in BRCA1/2 but also in MSH2, PMS2, CHEK2, and PALB2, the proportion of PV in BRCA1/2 was estimated to be over 88%, indicating the need to focus genetic testing and management efforts more on these two genes.

Recently, the US Preventive Services Task Force updated its recommendations on risk assessment, genetic counseling, and genetic testing for BRCA-related cancers in women as follows: “primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with BRCA1/2 gene mutations with an appropriate brief familial risk assessment tool. Women with a positive result on the risk assessment tool should receive genetic counseling and, if indicated after counseling, genetic testing. (B recommendation)” [5].

This issue of Ann Lab Med also presents a review article by Lee, et al. [6], which outlines treatment and prevention strategies for patients with BRCA-related breast cancer. It also covers recent advances in the management of BRCA-related breast cancer by treatment with poly (ADP-ribose) polymerase (PARP) inhibitors.